Terns Pharmaceuticals Inc (STU:430)
€ 5.6 0.05 (0.9%) Market Cap: 470.26 Mil Enterprise Value: 113.82 Mil PE Ratio: 0 PB Ratio: 1.34 GF Score: 41/100

Terns Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 04:30PM GMT
Release Date Price: €11.1 (+0.54%)
Mia Moss
Jefferies - Analyst

(inaudible) morning, and welcome to the Jefferies Global Healthcare Conference. My name is Mia Moss with the Jefferies Investment Banking team. And it's my great pleasure to introduce Erin Quirk, President, Head of R&D at Terns Pharma. Thank you.

Erin Quirk
Terns Pharmaceuticals, Inc. - President, Head of Research & Development

Thanks so much for that introduction, Mia, and thanks to the entire Jefferies team for the opportunity to be here today and present Terns Pharmaceuticals. So as always, I'd invite you to take a look at our forward-looking statements, which are listed in full on our website.

So Terns is a publicly traded pharmaceutical company based in San Francisco. We're developing small molecule medicines with clinically validated mechanisms of action to address important and serious diseases, including oncology and metabolic diseases with high unmet need. We have discovered three assets internally in three different classes with validated mechanisms, where we think the molecules that we have discovered

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot